Author

Claudine Egger

Observed name: Egger, Claudine

Institution: Spital Limmattal

Observed institution: Spital Limmattal

ORCID: 0000-0002-5081-8279

Observed ORCID: 0000-0002-5081-8279

OpenAlex ID: A5113250445

The Effect of Collaborative Reviews of Electronic Patient-Reported Outcomes on the Congruence of Patient- and Clinician-Reported Toxicity in Cancer Patients Receiving Systemic Therapy: Prospective, Multicenter, Observational Clinical Trial

2021 · Andreas Trojan, Nicolas Leuthold, et al. · Journal of Medical Internet Research · 13

Prevalence of symptomatic skeletal events (SSE) with reduced denosumab (Dmab) dose density (every 12 weeks versus every 4 weeks): A randomized phase III non-inferiority trial SAKK 96/12 REDUSE.

2026 · Roger Anton Fredy Von Moos, Andreas Müller, et al. · Journal of Clinical Oncology · 4

Osteonecrosis of the jaw (ONJ) in patients with metastatic castration resistant prostate cancer (mCRPC) treated with denosumab in a randomized phase III trial comparing 4 vs. 12 weekly administration (REDUSE, SAKK 96/12).

2025 · Arnoud J. Templeton, Stefanie Hayoz, et al. · Journal of Clinical Oncology · 2

Incidence of osteonecrosis of the jaw (ONJ) in the randomized non-inferiority phase III trial SAKK 96/12 REDUSE comparing denosumab (DN) administered every 4 weeks (q4w) versus every 12 weeks (q12w).

2024 · Roger Anton Fredy Von Moos, Andreas Mueller, et al. · Journal of Clinical Oncology · 1

Case Report: Metastatic colorectal cancer with ALK–CEP44 fusion and rapid resistance development

2025 · Silvan Hofmann, Claudine Egger, et al. · Frontiers in Oncology

Abstract PS5-06: Osteonecrosis of the jaw (ONJ) in patients with metastatic breast cancer treated with denosumab in a randomized phase III trial comparing 4 vs. 12 weekly administration (REDUSE, SAKK 96/12)

2025 · Andreas Müller, Arnoud J Templeton, et al. · Clinical Cancer Research

Works count: 7

Citation count: 20

H-index: 2

I10-index: 1